Nathaniel Robert Ranney, M.D. Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 131 Cherokee Rose Ln Ste B, Covington, LA 70433 Phone: 985-871-1721 Fax: 985-893-6908 |
Felix G. Rabito Jr., M.D. Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 131 Cherokee Rose Ln, Covington, LA 70433 Phone: 985-871-1721 Fax: 985-871-4049 |
Glenn D. Hedgpeth, MD Internal Medicine - Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 189 Greenbriar Blvd, Suite C, Covington, LA 70433 Phone: 985-871-8920 Fax: 985-871-9796 |
Catherine J. Murray, M.D. Internal Medicine - Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 131 Cherokee Rose Ln, Covington, LA 70433 Phone: 985-871-1721 Fax: 985-871-4049 |
News Archive
Compugen Ltd. announced today the discovery and initial experimental validation of CGEN-928 as a drug target for the treatment of multiple myeloma. In recently completed studies, CGEN-928, a membrane protein which previously had no known function or potential clinical utility, demonstrated broad expression in human multiple myeloma tumor cells, including drug resistant and aggressive primary tumor cell lines.
New data presented today further demonstrate the efficacy of Instanyl in management of breakthrough cancer pain. The data which were presented at the 6th congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC) are from a multinational, crossover trial comparing Instanyl with oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in patients with cancer.
Patients who undergo hemodialysis on a frequent basis are at an increased risk for vascular access complications, requiring more vascular repair procedures to enable continued access to the blood, report Canadian researchers.
Dyax Corp. today announced that it has launched its newly enhanced product website, www.KALBITOR.com, featuring its comprehensive financial assistance program. KALBITOR (ecallantide) is approved for the treatment of acute attacks of hereditary angioedema in patients 16 years of age and older.
› Verified 9 days ago